Home › Oropharyngeal Cancer › California › San Diego
Oropharyngeal Cancer clinical trials in San Diego, CA
4 studies for Oropharyngeal Cancer are looking for participants at sites in and around San Diego (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- UC San Diego Health - Moores Cancer Center, La Jolla · 11 mi away
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
RecruitingPhase 2/3
- Medical Oncology Associates of San Diego, San Diego
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
RecruitingPhase 3
- Moores Cancer Center, San Diego
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- UC San Diego Medical Center - Hillcrest, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi away
Oropharyngeal Cancer trials in other cities
- Chicago, IL9 studies
- Edison, NJ8 studies
- Atlanta, GA7 studies
- New York City, NY7 studies
- St. Louis, MO7 studies
- Omaha, NE7 studies
- Tampa, FL6 studies
- Houston, TX6 studies
- Detroit, MI6 studies
- Baltimore, MD6 studies
- Pittsburgh, PA6 studies
- Los Angeles, CA6 studies
Other studies in San Diego
- Non-Small Cell Lung Cancer49 studies
- Breast Cancer41 studies
- Prostate Cancer32 studies
- Cancer (all types)31 studies
- Metastatic Cancer29 studies
- Lung Cancer26 studies
- Pancreatic Cancer24 studies
- Obesity24 studies
- Ovarian Cancer24 studies
- Colorectal Cancer22 studies
- Heart Failure22 studies
- Type 2 Diabetes21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.